Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Depreciation and Depletion: 2013-2024

Historic Depreciation and Depletion for Akebia Therapeutics (AKBA) over the last 12 years, with Dec 2024 value amounting to $1.5 million.

  • Akebia Therapeutics' Depreciation and Depletion fell 12.40% to $318,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 15.65%. This contributed to the annual value of $1.5 million for FY2024, which is 7.76% down from last year.
  • Per Akebia Therapeutics' latest filing, its Depreciation and Depletion stood at $1.5 million for FY2024, which was down 7.76% from $1.6 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Depreciation and Depletion registered a high of $2.1 million during FY2020, and its lowest value of $1.5 million during FY2024.
  • Moreover, its 3-year median value for Depreciation and Depletion was $1.6 million (2023), whereas its average is $1.6 million.
  • Data for Akebia Therapeutics' Depreciation and Depletion shows a maximum YoY declined of 12.95% (in 2022) over the last 5 years.
  • Akebia Therapeutics' Depreciation and Depletion (Yearly) stood at $2.1 million in 2020, then decreased by 9.52% to $1.9 million in 2021, then decreased by 12.95% to $1.7 million in 2022, then fell by 4.17% to $1.6 million in 2023, then dropped by 7.76% to $1.5 million in 2024.